Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $5.8 million.

  • Dianthus Therapeutics' Share-based Compensation rose 5088.54% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.7 million, marking a year-over-year increase of 11369.82%. This contributed to the annual value of $12.9 million for FY2024, which is 34462.07% up from last year.
  • Dianthus Therapeutics' Share-based Compensation amounted to $5.8 million in Q3 2025, which was up 5088.54% from $5.7 million recorded in Q2 2025.
  • Dianthus Therapeutics' Share-based Compensation's 5-year high stood at $5.8 million during Q3 2025, with a 5-year trough of $462000.0 in Q2 2023.
  • Moreover, its 4-year median value for Share-based Compensation was $1.9 million (2022), whereas its average is $2.5 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 7495.93% in 2023, then skyrocketed by 57121.21% in 2024.
  • Quarter analysis of 4 years shows Dianthus Therapeutics' Share-based Compensation stood at $513000.0 in 2022, then surged by 41.52% to $726000.0 in 2023, then surged by 439.67% to $3.9 million in 2024, then skyrocketed by 47.88% to $5.8 million in 2025.
  • Its Share-based Compensation was $5.8 million in Q3 2025, compared to $5.7 million in Q2 2025 and $5.3 million in Q1 2025.